Description:

Gynecologic Oncology Group Cycle Dose Drug Form (Form D2R) Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT00951496 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4F53E994-CCD2-730F-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4F53E994-CCD2-730F-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 9/19/12
  2. 1/8/15
  3. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Cycle Dose Drug Form D2R Fallopian Tube Cancer (NCT00951496)

No Instruction available.

  1. StudyEvent: Gynecologic Oncology Group Cycle Dose Drug Form (Form D2R)
    1. No Instruction available.
Header Module
Treatment Cycle And Modification
Cycle Delayed?
Cycle delayed reason
Dose modification status
Dose Modification (Change)
Dose Modification Reason
Adverse Event
Kg
m2
Performance status (Zubrod)
Pretreatment Hematology And Chemistry Values
g/dL
1000/uL
1000/uL
1000/uL
seconds
mg/dL
mg/dL

Similar models